The Impact of PET/CT on Paediatric Oncology.

This review paper will discuss the use of positron emission tomography/computed tomography (PET/CT) in paediatric oncology. Functional imaging with PET/CT has proven useful to guide treatment by accurately staging disease and limiting unnecessary treatments by determining the metabolic response to treatment. F-Fluorodeoxyglucose (2-[F]FDG) PET/CT is routinely used in patients with lymphoma.

[Ga]Ga-NODAGAZOL uptake in atherosclerotic plaques correlates with the cardiovascular risk profile of patients.

Objectives: This study aimed to determine the correlation of [Ga]Ga-NODAGA uptake in atherosclerotic plaques and the cardiovascular risk profile of patients imaged with positron emission tomography (PET), wherein quantification of uptake was determined by atherosclerotic plaque maximum target-to-background ratio (TBRmax). We also correlated uptake with a history of cardiovascular events.

Methods: We included patients who underwent PET/CT imaging post-injection of [Ga] Ga-NODAGA.

Ga-PSMA-11 PET/CT Initial Staging in Black and White South African Males with ISUP Grade Group 1 and 2 Prostate Adenocarcinoma.

Prostate adenocarcinoma (PCa) is a leading cause of mortality. Black males with high-risk PCa have a poorer prognosis compared to white males. Patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 and 2 PCa have little potential for metastases post radical prostatectomy.

Hematologic toxicity profile and efficacy of [Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.

Purpose: Actinium-225-labeled prostate-specific membrane antigen ([Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC. We aimed to investigate the hematologic toxicity and efficacy of [Ac]Ac-PSMA-617 therapy in patients with extensive skeletal metastases of mCRPC.

The Use of F-FDG PET/CT Metabolic Parameters in Predicting Overall Survival in Patients Undergoing Restaging for Malignant Melanoma.

Malignant melanoma is one of the more aggressive cancers in the skin, with an increasing incidence every year. Melanoma has a better prognosis if diagnosed early and survival tends to decrease once the disease has metastasized. Positron emission tomography (PET) with 2-[F]fluoro-2-deoxy-D-glucose (F-FDG) has been used extensively over the past two decades in staging and assessing responses to therapy in patients with melanoma.

A Prospective Investigation of Tumor Hypoxia Imaging with Ga-Nitroimidazole PET/CT in Patients with Carcinoma of the Cervix Uteri and Comparison with F-FDG PET/CT: Correlation with Immunohistochemistry.

Hypoxia in cervical cancer has been associated with a poor prognosis. Over the years Ga labelled nitroimidazoles have been studied and have shown improved kinetics. We present our initial experience of hypoxia Positron Emission Tomography (PET) imaging in cervical cancer with Ga-Nitroimidazole derivative and the correlation with F-FDG PET/CT and immunohistochemistry.